SlideShare a Scribd company logo
2
Most read
3
Most read
4
Most read
1 
HYPERCALCIURIA: A REVIEW OF LITERARURE 
Dr. Manoj R. Kandoi 
Hypercalciuria is defined as the excretion of urinary calcium in excess of 4mg/kg of body weight per day 
while on a regular, unrestricted diet or excretion of urinary calcium and 100mEq sodium) diet. 
Etiology: These include: 
1. Absorptive hypercalciuria. 
2. Renal leak hypercalciuria. 
3. Resorptive hypercalciuria. 
4. Renal phosphate leak. 
5. Vitamin D intoxication. 
6. Endocrinal disorders. Hyperparathyroidism, Addison disease and glucocorticoid excess. 
7. Neoplastic conditions: Multiple myeloma, lymphoma, leukemia, metastatic bone tumors and 
para-neoplastic syndromes. 
8. Renal conditions: Renal tubular acidosis, Albright tubular acidosis. 
9. Sarcoidosis and other granulomatous disease. 
10. Prolonged immobilization. 
Clinical significance: 
· About 80% of all kidney stones contain calcium. 
· At least one third of all calcium stone formers have clinically detectable hypercalciuria. 
· Hypercalciuria results in kidney stone disease and osteoporosis. 
· Besides hypercalciuria other causes of kidney stone diseases are hyperoxaluria, hyperuricosuria, 
low urinary volume and hypocitraturia. 
Role of dietary factors in hypercalciuria: 
· Calcium intake: Dietary calcium is known to prevent absoption of intestinal oxalate. Any 
increase in stone formation risk due to additional calcium intake is more than compensated for 
by the reduction in oxaluria. Hence complete restriction of calcium is not advisable and 
recommended intake is about 600-800mg calcium per day. 
In general each 100mg of daily dietary calcium increases urinary calcium by 8mg/day in a healthy 
population but raises urinary calcium by 20mg/day. 2000mg of calcium per day will result in 
hypercalciuria or hypercalcemia in calcium stone formers. 
· Animal protein: Excessive animal protein (>1.7g/kg of body weight) causes increased acid load in 
the body which is neutralized by calcium release from skeleton which may exacerbate 
hypercalciuria. Acid loading is also known to directly inhibit renal calcium reabsorption. 
· Sodium content: Each 100mEg increase in daily sodium intake raises urinary calcium excretion 
by about 50mg/day. It causes calcium release from bone, increases urinary calcium excretion by 
PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
2 
its direct effect on kidney and reduces the hypocalciuric effect of thiazide therapy in 
hypercalciuria. 
· Alcohol and caffeine intake: These increase intestinal urinary calcium excretion. 
· Refined carbohydrate: These increase intestinal absorption of calcium. 
Path physiology of absorptive hypercalciuria: 
Absorptive hypercalciuria can be classified into 3 types: 
Type I: It is the most severe and less common type of hypercalciuria. The variant is unresorptive to 
dietary modifications such as dietary calcium restrictions but urinary calcium excretion normalizes 
during periods of fasting. 
Type II: This commonest variant is responsive to moderate dietary calcium restriction. 
Type III: This rare variant is associated with a renal defect that causes excessive urinary phosphate 
excretion with resultant hypophosphatemia. Hypophosphatemia causes activation of vitamin-D3 which 
in turn increases intestinal absorption of both calcium and phosphate. This excess calcium absorbed 
leads to absorptive hypercalciuria. 
Other problems to be considered: These include: 
· Hypervitaminosis D 
· Hypercalcemic nephropathy 
· Nephrolithiasis 
· Hypercalcemia 
· Hyperoxaluria 
· Hyperparathyroidism 
· Hypophosphatemia 
Laboratory studies: 
1. Blood examination: This includes: 
a. Serum calcium, phosphorus and alkaline phosphatase. 
b. Serum electrolytes 
c. Serum uric acid 
d. Serum PTH essay 
e. Serum vitamin D and Vitamin D3 in selected cases. 
2. 24 hours urine examination: The tests usually performed are: 
· Calcium 
· Oxalate 
· pH 
· Volume 
· Creatinine 
PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
3 
· Specific gravity 
· Phosphate 
· Citrate 
· Sodium 
Treatment approach: It essentially comprises of: 
1. Full medical history with blood 24-hour urine testing. 
2. Hypercalciuria should be confirmed first. 
3. Rule out hyperparathyroidism (serum PTH levels) and hyposhosphatemia. 
4. A therapeutic trial of dietary modification is given. 
5. Laboratory tests are repeated. 
6. If patient responds to dietary modification, continue the same treatment and do periodical 
laboratory tests. 
7. Patient not responding to dietary modification may require treatment with thiazide diuretics, 
Ortho-phosphates, biphosphonates or sodium cellulose phosphate. 
Dietary modifications: 
1. Daily calcium intake must be limited to 600-800 mg/day. 
2. Dietary oxalate intake should be reduced. Foods rich in oxalates include nuts, colas, teas, green 
leafy vegetables, chocolate, vegetable products. 
3. Intake of purines and animal protein should be less than 1.7gm/kg of body weight. 
4. Refined sugar and salt (sodium) should be reduced to maximum possible. 
5. Alcohol and caffeine intake should be restricted. 
6. Water intake should be sufficient to produce at least 2 litre/day of urine. 
7. Dietary fiber intake should be increased (12-24gm/day). 
Medications: 
1. Thiazide and related drugs: These are specially useful in patients with hypercalciuria with hyper 
tension or osteoporosis. These are also indicated in renal leak hypercalciuria where these can 
prevent secondary hyperparathyroidism, normalize vitamin D3 synthesis, calcium absorption 
and urinary calcium excretion. In absorptive hypercalciuria, thiazide diuretics should be used 
with caution as hypercalcemia may result. 
Adverse effects of these drugs include precipitation of gout, dehydration, hypokalemia and 
hyponatremia. Patients may report muscle aches, depression, decreased libido, generalized 
weakness and malaise. Since thiazides are chemically sulfonamides, these should be used 
cautiously in patients with history of sulfonamides, allergy. Drug interactions with other drugs 
such as alcohol, narcotics, muscle relaxants, barbitutrates, antidiabeties, lithium and 
nonsteroidal anti-inflammatory agents. 
2. Orthophosphates: Orthophosphates reduce 24 hour urinary calcium excretion and increase 
urinary stone inhibitors such as citrate and pyrophosphate. These are especially indicated in 
cases of absorptive hypercalciuria and when thiazide cannot be used or are ineffective. The 
PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
4 
dosage used is 1-2.5 gm/day taken at regular intervals. The adverse effects include diarrhea, 
bloating and gastrointestinal upset. 
3. Biphosphonates: These are known to benefit in hypercalcemia and hypercalciuria by inhibitory 
osteoclastic activity. These are especially indicated in hypercalciuric stone formers with 
associated osteoporosis. These can also be in cases of hypercalciuria when other measures are 
unsuccessful or poorly tolerated. 
4. Sodium cellulose phosphate: The calcium binding action of sodium cellulose phosphate is due 
to sodium ion exchange for calcium in intestine. The calcium is then excreted bound to the 
cellulose in the stool. 
The side effects of these drugs include excessive oxalate absorption (due to lack of calcium 
availability for binding with oxalate) and magnesium deficiency (as cellulose phosphate also 
binds with magnesium). Hence it is advisable to provide magnesium supplementation and 
restrict oxalate intake. 
Follow-up: 
· Regular 24 hour urine testing and blood tests should be done until the hypercalciuria is 
controlled and stable. 
· Routine KUB x-rays are needed to find any newly formed stones. 
Treatment of osteoporosis complicated with hypercalciuria: 
The patient with combined osteoporosis and hypercalciuria should have the following laboratory work-up 
done: 
· 24 hour urine excretion levels to confirm hypercalciuria. 
· Serum calcium levels to determine hypercalciuria. 
· Serum PTH essay in detected cases of hypercalciuria. 
Patients with hypercalciuria with no hypercalcemia do well with thiazide therapy which reduces urinary 
calcium excretion and elevates serum calcium levels. 
In other situations estrogen, biphosphonates are good therapeutic option. 
Calcium supplementation if needed should be in the form of calcium citrate as its citrate component 
limits any increased stone formation. It should be preceded by thiazide therapy to correct 
hypercalciuria. The urinary calcium levels need to be monitored carefully and other risk factors such as 
uric acid, hypovolumia, oxalate, magnesium etc should be optimized. 
Further readings: 
1. Schmiedl A, Schwille PO. Is magnesium a marker of disordered mineral metabolism in males 
with idiopathic recurrent calcium urolithiasis? Observations focusing on fasting magnesiuria and 
magnesiemia, protein and other substances in urine and plasma. Magnes Res. 2003 Sep; 
16(3):192-205. 
PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
5 
2. Ardito G, Fadda G, Danese D, Modugno P, Giordano A, Revelli L, Ardito F, Pontecorvi A. 
Coexistence of a parathyroid adenoma and parathyroid cyst causing primary 
hyperparathyroidism. J Endocrinol Invest. 2003 Jul;26(7):679-82 
3. Rogowska-Kalisz A, Tkaczyk M, Bilinska W, Nowicki M. {In Process Citation} Pol Merkuriusz Lek. 
2003 Jul; 15(85):51-4. 
4. Carbone LD, Bush AJ, Barrow KD, Kang AH. The relationship of sodium intake to calcium and 
sodium excretion and bone mineral density of the hip in postmenopausal African-American and 
Caucasian women. J Bone Miner Metab. 2003; 21(6):415-20. 
5. Tajima T, Nakae J, Fujieda K. Two heterozygous mutations of CLDN16 in a Japanese patient with 
FHHNC. Pediatr Nephrol. 2003 Oct 30. 
6. Claverie-Martin F, Gonzalez-Acosta H, Flores C, Anton-Gamero M, Garcia-Nieto V. De novo 
insertion of an Alu sequence in the coding region of the CLCN5 gene results in Dent’s disease. 
Hum Genet. 2003 Nov; 113(6):480-5. 
7. Ceran O, Akin M, Akturk Z, Ozkozaci T. Normal urinary calcium/creatinine ratios in Turkish 
children. Indian Pediatr. 2003 Sep; 40(9):884-7. 
8. Nicolaidou P, Georgouli H, Getsi V, Tsapra H, Psychou F, Matsinos YG, Zeis PM, Gourgiotis D. 
Urinary excretion of endothelin-I in children with absorptive idiopathic hypercalciuria. Pediatr 
Nephrol. 2003 Nov; 18(11):1157-60. 
9. Carr G, Simmons N, Sayer J. A role for CBS domain 2 in trafficking of chloride channel CLC-5. 
Biochem Biophys Res Commun. 2003 Oct 17; 310(2):600-5. 
10. Ammenti A, Nitsch M. Hypercalciuria in osteogenesis imperfect type I. Klin Padiatr. 2003 Sep- 
Oct; 215(5):283-5. 
11. Schwartz AV. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int. 2003 Oct 2. 
12. Colston KW, Pirianov G, Bramm E, Hamberg KJ, Binderup L. Effects of Seocalcitol (EB1089) on 
nitrosomethyl Urea-induced rat mammary tumors. Breast cancer Res Treat. 2003 Aug; 
80(3):303-11. 
13. Aceto G, Penza R, Coccioli MS, Palumbo F, Cresta L, Cimador M, Chiozza ML, Caione P. Enuresis 
subtypes based on nocturnal hypercalciuria: a multicenter study. J Urol. 2003 Oct; 170(4 Pt 
2):1670-3. 
14. Negri AL, Spivacow R, Del Valle E, Fradinger E, Marino A, Zanchetta JR. Renal phosphate leak in 
patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urol Res. 2003 Sep 13. 
15. Garcia-Nieto V, Navarro JF, Monge M, Garcia-Rodriguez VE. Bone mineral density in girls and 
their mothers with idiopathic hypercalciuria. Nephron Clin Pract. 2003; 94(4):c89-93. 
16. Weisinger JR. Bone mineral density in idiopathic hypercalciuria:the chicken or the egg? Nephron 
Clin Pract. 2003; 94(4):c81-2. 
17. Rake JP, Visser G, Huismans D, Huitema S, van der Veer E, Piers DA, Smit GP. Bone mineral 
density in children adolescents and adults with glycogen storage disease type Ia: a cross-sectional 
and longitudinal study. J Inherit Metab Dis. 2003; 26(4):371-84. 
18. Winer KK, Ko CW, Reynolds JC, Doedy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB 
Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing 
parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003 Sep; 
88(9):4214-20. 
PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
6 
19. Mittal RD, Kumar R, Mittl B, Prasad R, Bhandari M. Stone composition, Metabolic Profile and 
the Presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal 
stone formation. Med Princ Pract. 2003 Oct-Dec; 12(4):208-13. 
20. Ogawa Y, Yonou H, Hokama S, Oda M, Morozumi M, Sugaya K. Urinary saturation and risk 
factors for calcium oxalate stone disease based on spot and 24-hour urine specimens. Front 
Biosci. 2003 Sep 1; 8:a167-76. 
PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com

More Related Content

PPTX
Scorpion sting in children
PPTX
Pediatric thrombocytopenia
PPT
approach to hyponatremia in children
PPTX
Child with lymphadenopathy
PPTX
PAEDIATRICS HIV
PPTX
Approach to anemia in children
PDF
von Willebrand disease
PPTX
Thyroid disorders in children
Scorpion sting in children
Pediatric thrombocytopenia
approach to hyponatremia in children
Child with lymphadenopathy
PAEDIATRICS HIV
Approach to anemia in children
von Willebrand disease
Thyroid disorders in children

What's hot (20)

PPTX
Posterior Urethral Valve
PDF
Hypothyroidism in children 2021
PPTX
Hyponatremia in children
PPTX
Hyperparathyroidism in children
PPTX
Renal tubular acidosis (pediatrics)
PPT
DKA in children
PPTX
Approach to an unconcious child
PPTX
Pediatric Urinary Tract infections
PPTX
Renal Papillary Necrosis.pptx
PPTX
TORCH INFECTION
PPTX
Obstructive uropathy in neonates
PPT
Minimal change disease
PDF
Congenital anomalies of kidney and urinary tract
PPTX
Red Cell Physiology & Pathophysiology of Sickle Cell Disease
PDF
Rickets in children
PPTX
FEVER OF UNKNOWN ORIGIN - PEDIATRICS
PPTX
scrub typhus
PDF
Acute leukemia in children 2021
PDF
Pediatric urology :Posterior Urethral Valve (PUV)- diagnosis & management
PPT
Approach to a child with Hepatosplenomegaly
Posterior Urethral Valve
Hypothyroidism in children 2021
Hyponatremia in children
Hyperparathyroidism in children
Renal tubular acidosis (pediatrics)
DKA in children
Approach to an unconcious child
Pediatric Urinary Tract infections
Renal Papillary Necrosis.pptx
TORCH INFECTION
Obstructive uropathy in neonates
Minimal change disease
Congenital anomalies of kidney and urinary tract
Red Cell Physiology & Pathophysiology of Sickle Cell Disease
Rickets in children
FEVER OF UNKNOWN ORIGIN - PEDIATRICS
scrub typhus
Acute leukemia in children 2021
Pediatric urology :Posterior Urethral Valve (PUV)- diagnosis & management
Approach to a child with Hepatosplenomegaly
Ad

Viewers also liked (10)

PPT
Haematuria & Renal Failure
PPTX
Approach to patient with hypo/hyper calcaemia
PPT
Urinary stone evaluation in laboratory and clinical significance
PPTX
Nutri report
PPTX
Urolithiasis
PPT
Hypercalcemia
PPT
Urinary disorders watson
PPT
Normal constituents of urine
PPTX
Renal calculi ppt
Haematuria & Renal Failure
Approach to patient with hypo/hyper calcaemia
Urinary stone evaluation in laboratory and clinical significance
Nutri report
Urolithiasis
Hypercalcemia
Urinary disorders watson
Normal constituents of urine
Renal calculi ppt
Ad

Similar to Hypercalciuria (20)

PPTX
Hyper and hypocalcemia
PPTX
How to approach hypercalcaemia?
PPTX
HYPERCALCEMIA AND HYPOCALCEMIA fina.pptx
DOC
Minerals
DOC
Minerals
PPT
Major intra extracellular electrolyes
PPTX
Testing parathyroid hormone disorders.pptx
PPTX
Parathyroid disorders.pptx
PDF
4. Renal failure for nursing student imporatance.pdf
PPTX
Chronic renal failure.pptx
PPTX
PARATHYROID AND ANAESTHESIA BRIEF APPROCH .pptx
PDF
CALCIUM - ELECTROLYTE IMBALANCE (HYPERCALCEMIA & HYPOCALCEMIA).pdf
PPT
parathyroid disorder
PPTX
15- NURSING CARE OF Liver cirrhosis.pptx
PPT
Hypercalcemia in children and adolescent
PPTX
Haematopoetic agents
PPTX
Parathyroid Disorder.pptx for bachelor of nursing
PPTX
Approach to Hypercalcemia
PPTX
HYPERCALCEMIA : :::: CALCIUM HOMEOSTASIS
PPSX
Iron toxicity
Hyper and hypocalcemia
How to approach hypercalcaemia?
HYPERCALCEMIA AND HYPOCALCEMIA fina.pptx
Minerals
Minerals
Major intra extracellular electrolyes
Testing parathyroid hormone disorders.pptx
Parathyroid disorders.pptx
4. Renal failure for nursing student imporatance.pdf
Chronic renal failure.pptx
PARATHYROID AND ANAESTHESIA BRIEF APPROCH .pptx
CALCIUM - ELECTROLYTE IMBALANCE (HYPERCALCEMIA & HYPOCALCEMIA).pdf
parathyroid disorder
15- NURSING CARE OF Liver cirrhosis.pptx
Hypercalcemia in children and adolescent
Haematopoetic agents
Parathyroid Disorder.pptx for bachelor of nursing
Approach to Hypercalcemia
HYPERCALCEMIA : :::: CALCIUM HOMEOSTASIS
Iron toxicity

More from manoj kandoi (14)

PDF
Skin pdf
PDF
IACP Arthritis clinic Arthroplasty brochure
PDF
Infectious arthritis
PDF
Gouty arthritis
PDF
Resume manoj r.kandoi
PDF
Haemophilic arthritis
PDF
Low backache
PDF
Knee pain
PPT
Nobody loves life like him who is growing
DOC
Living with arthritis
PPT
Adult aquired flatfoot
DOC
Adshirwad hospital west profile
DOC
Ashirwad hospital east profile
PPT
Numbness in the extremities 2
Skin pdf
IACP Arthritis clinic Arthroplasty brochure
Infectious arthritis
Gouty arthritis
Resume manoj r.kandoi
Haemophilic arthritis
Low backache
Knee pain
Nobody loves life like him who is growing
Living with arthritis
Adult aquired flatfoot
Adshirwad hospital west profile
Ashirwad hospital east profile
Numbness in the extremities 2

Recently uploaded (20)

PDF
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
PDF
Plant-Based Antimicrobials: A New Hope for Treating Diarrhea in HIV Patients...
PDF
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
PDF
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
PPTX
Vaccines and immunization including cold chain , Open vial policy.pptx
PPTX
Neonate anatomy and physiology presentation
PDF
Calcified coronary lesions management tips and tricks
PDF
B C German Homoeopathy Medicineby Dr Brij Mohan Prasad
PPTX
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
PDF
AGE(Acute Gastroenteritis)pdf. Specific.
PPTX
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
PPTX
09. Diabetes in Pregnancy/ gestational.pptx
PPTX
Introduction to Medical Microbiology for 400L Medical Students
PPT
Rheumatology Member of Royal College of Physicians.ppt
PPTX
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha
PPT
Infections Member of Royal College of Physicians.ppt
PDF
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
PPTX
Acute Coronary Syndrome for Cardiology Conference
PPT
Dermatology for member of royalcollege.ppt
PPTX
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
Plant-Based Antimicrobials: A New Hope for Treating Diarrhea in HIV Patients...
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
Vaccines and immunization including cold chain , Open vial policy.pptx
Neonate anatomy and physiology presentation
Calcified coronary lesions management tips and tricks
B C German Homoeopathy Medicineby Dr Brij Mohan Prasad
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
AGE(Acute Gastroenteritis)pdf. Specific.
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
09. Diabetes in Pregnancy/ gestational.pptx
Introduction to Medical Microbiology for 400L Medical Students
Rheumatology Member of Royal College of Physicians.ppt
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha
Infections Member of Royal College of Physicians.ppt
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
Acute Coronary Syndrome for Cardiology Conference
Dermatology for member of royalcollege.ppt
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur

Hypercalciuria

  • 1. 1 HYPERCALCIURIA: A REVIEW OF LITERARURE Dr. Manoj R. Kandoi Hypercalciuria is defined as the excretion of urinary calcium in excess of 4mg/kg of body weight per day while on a regular, unrestricted diet or excretion of urinary calcium and 100mEq sodium) diet. Etiology: These include: 1. Absorptive hypercalciuria. 2. Renal leak hypercalciuria. 3. Resorptive hypercalciuria. 4. Renal phosphate leak. 5. Vitamin D intoxication. 6. Endocrinal disorders. Hyperparathyroidism, Addison disease and glucocorticoid excess. 7. Neoplastic conditions: Multiple myeloma, lymphoma, leukemia, metastatic bone tumors and para-neoplastic syndromes. 8. Renal conditions: Renal tubular acidosis, Albright tubular acidosis. 9. Sarcoidosis and other granulomatous disease. 10. Prolonged immobilization. Clinical significance: · About 80% of all kidney stones contain calcium. · At least one third of all calcium stone formers have clinically detectable hypercalciuria. · Hypercalciuria results in kidney stone disease and osteoporosis. · Besides hypercalciuria other causes of kidney stone diseases are hyperoxaluria, hyperuricosuria, low urinary volume and hypocitraturia. Role of dietary factors in hypercalciuria: · Calcium intake: Dietary calcium is known to prevent absoption of intestinal oxalate. Any increase in stone formation risk due to additional calcium intake is more than compensated for by the reduction in oxaluria. Hence complete restriction of calcium is not advisable and recommended intake is about 600-800mg calcium per day. In general each 100mg of daily dietary calcium increases urinary calcium by 8mg/day in a healthy population but raises urinary calcium by 20mg/day. 2000mg of calcium per day will result in hypercalciuria or hypercalcemia in calcium stone formers. · Animal protein: Excessive animal protein (>1.7g/kg of body weight) causes increased acid load in the body which is neutralized by calcium release from skeleton which may exacerbate hypercalciuria. Acid loading is also known to directly inhibit renal calcium reabsorption. · Sodium content: Each 100mEg increase in daily sodium intake raises urinary calcium excretion by about 50mg/day. It causes calcium release from bone, increases urinary calcium excretion by PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
  • 2. 2 its direct effect on kidney and reduces the hypocalciuric effect of thiazide therapy in hypercalciuria. · Alcohol and caffeine intake: These increase intestinal urinary calcium excretion. · Refined carbohydrate: These increase intestinal absorption of calcium. Path physiology of absorptive hypercalciuria: Absorptive hypercalciuria can be classified into 3 types: Type I: It is the most severe and less common type of hypercalciuria. The variant is unresorptive to dietary modifications such as dietary calcium restrictions but urinary calcium excretion normalizes during periods of fasting. Type II: This commonest variant is responsive to moderate dietary calcium restriction. Type III: This rare variant is associated with a renal defect that causes excessive urinary phosphate excretion with resultant hypophosphatemia. Hypophosphatemia causes activation of vitamin-D3 which in turn increases intestinal absorption of both calcium and phosphate. This excess calcium absorbed leads to absorptive hypercalciuria. Other problems to be considered: These include: · Hypervitaminosis D · Hypercalcemic nephropathy · Nephrolithiasis · Hypercalcemia · Hyperoxaluria · Hyperparathyroidism · Hypophosphatemia Laboratory studies: 1. Blood examination: This includes: a. Serum calcium, phosphorus and alkaline phosphatase. b. Serum electrolytes c. Serum uric acid d. Serum PTH essay e. Serum vitamin D and Vitamin D3 in selected cases. 2. 24 hours urine examination: The tests usually performed are: · Calcium · Oxalate · pH · Volume · Creatinine PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
  • 3. 3 · Specific gravity · Phosphate · Citrate · Sodium Treatment approach: It essentially comprises of: 1. Full medical history with blood 24-hour urine testing. 2. Hypercalciuria should be confirmed first. 3. Rule out hyperparathyroidism (serum PTH levels) and hyposhosphatemia. 4. A therapeutic trial of dietary modification is given. 5. Laboratory tests are repeated. 6. If patient responds to dietary modification, continue the same treatment and do periodical laboratory tests. 7. Patient not responding to dietary modification may require treatment with thiazide diuretics, Ortho-phosphates, biphosphonates or sodium cellulose phosphate. Dietary modifications: 1. Daily calcium intake must be limited to 600-800 mg/day. 2. Dietary oxalate intake should be reduced. Foods rich in oxalates include nuts, colas, teas, green leafy vegetables, chocolate, vegetable products. 3. Intake of purines and animal protein should be less than 1.7gm/kg of body weight. 4. Refined sugar and salt (sodium) should be reduced to maximum possible. 5. Alcohol and caffeine intake should be restricted. 6. Water intake should be sufficient to produce at least 2 litre/day of urine. 7. Dietary fiber intake should be increased (12-24gm/day). Medications: 1. Thiazide and related drugs: These are specially useful in patients with hypercalciuria with hyper tension or osteoporosis. These are also indicated in renal leak hypercalciuria where these can prevent secondary hyperparathyroidism, normalize vitamin D3 synthesis, calcium absorption and urinary calcium excretion. In absorptive hypercalciuria, thiazide diuretics should be used with caution as hypercalcemia may result. Adverse effects of these drugs include precipitation of gout, dehydration, hypokalemia and hyponatremia. Patients may report muscle aches, depression, decreased libido, generalized weakness and malaise. Since thiazides are chemically sulfonamides, these should be used cautiously in patients with history of sulfonamides, allergy. Drug interactions with other drugs such as alcohol, narcotics, muscle relaxants, barbitutrates, antidiabeties, lithium and nonsteroidal anti-inflammatory agents. 2. Orthophosphates: Orthophosphates reduce 24 hour urinary calcium excretion and increase urinary stone inhibitors such as citrate and pyrophosphate. These are especially indicated in cases of absorptive hypercalciuria and when thiazide cannot be used or are ineffective. The PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
  • 4. 4 dosage used is 1-2.5 gm/day taken at regular intervals. The adverse effects include diarrhea, bloating and gastrointestinal upset. 3. Biphosphonates: These are known to benefit in hypercalcemia and hypercalciuria by inhibitory osteoclastic activity. These are especially indicated in hypercalciuric stone formers with associated osteoporosis. These can also be in cases of hypercalciuria when other measures are unsuccessful or poorly tolerated. 4. Sodium cellulose phosphate: The calcium binding action of sodium cellulose phosphate is due to sodium ion exchange for calcium in intestine. The calcium is then excreted bound to the cellulose in the stool. The side effects of these drugs include excessive oxalate absorption (due to lack of calcium availability for binding with oxalate) and magnesium deficiency (as cellulose phosphate also binds with magnesium). Hence it is advisable to provide magnesium supplementation and restrict oxalate intake. Follow-up: · Regular 24 hour urine testing and blood tests should be done until the hypercalciuria is controlled and stable. · Routine KUB x-rays are needed to find any newly formed stones. Treatment of osteoporosis complicated with hypercalciuria: The patient with combined osteoporosis and hypercalciuria should have the following laboratory work-up done: · 24 hour urine excretion levels to confirm hypercalciuria. · Serum calcium levels to determine hypercalciuria. · Serum PTH essay in detected cases of hypercalciuria. Patients with hypercalciuria with no hypercalcemia do well with thiazide therapy which reduces urinary calcium excretion and elevates serum calcium levels. In other situations estrogen, biphosphonates are good therapeutic option. Calcium supplementation if needed should be in the form of calcium citrate as its citrate component limits any increased stone formation. It should be preceded by thiazide therapy to correct hypercalciuria. The urinary calcium levels need to be monitored carefully and other risk factors such as uric acid, hypovolumia, oxalate, magnesium etc should be optimized. Further readings: 1. Schmiedl A, Schwille PO. Is magnesium a marker of disordered mineral metabolism in males with idiopathic recurrent calcium urolithiasis? Observations focusing on fasting magnesiuria and magnesiemia, protein and other substances in urine and plasma. Magnes Res. 2003 Sep; 16(3):192-205. PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
  • 5. 5 2. Ardito G, Fadda G, Danese D, Modugno P, Giordano A, Revelli L, Ardito F, Pontecorvi A. Coexistence of a parathyroid adenoma and parathyroid cyst causing primary hyperparathyroidism. J Endocrinol Invest. 2003 Jul;26(7):679-82 3. Rogowska-Kalisz A, Tkaczyk M, Bilinska W, Nowicki M. {In Process Citation} Pol Merkuriusz Lek. 2003 Jul; 15(85):51-4. 4. Carbone LD, Bush AJ, Barrow KD, Kang AH. The relationship of sodium intake to calcium and sodium excretion and bone mineral density of the hip in postmenopausal African-American and Caucasian women. J Bone Miner Metab. 2003; 21(6):415-20. 5. Tajima T, Nakae J, Fujieda K. Two heterozygous mutations of CLDN16 in a Japanese patient with FHHNC. Pediatr Nephrol. 2003 Oct 30. 6. Claverie-Martin F, Gonzalez-Acosta H, Flores C, Anton-Gamero M, Garcia-Nieto V. De novo insertion of an Alu sequence in the coding region of the CLCN5 gene results in Dent’s disease. Hum Genet. 2003 Nov; 113(6):480-5. 7. Ceran O, Akin M, Akturk Z, Ozkozaci T. Normal urinary calcium/creatinine ratios in Turkish children. Indian Pediatr. 2003 Sep; 40(9):884-7. 8. Nicolaidou P, Georgouli H, Getsi V, Tsapra H, Psychou F, Matsinos YG, Zeis PM, Gourgiotis D. Urinary excretion of endothelin-I in children with absorptive idiopathic hypercalciuria. Pediatr Nephrol. 2003 Nov; 18(11):1157-60. 9. Carr G, Simmons N, Sayer J. A role for CBS domain 2 in trafficking of chloride channel CLC-5. Biochem Biophys Res Commun. 2003 Oct 17; 310(2):600-5. 10. Ammenti A, Nitsch M. Hypercalciuria in osteogenesis imperfect type I. Klin Padiatr. 2003 Sep- Oct; 215(5):283-5. 11. Schwartz AV. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int. 2003 Oct 2. 12. Colston KW, Pirianov G, Bramm E, Hamberg KJ, Binderup L. Effects of Seocalcitol (EB1089) on nitrosomethyl Urea-induced rat mammary tumors. Breast cancer Res Treat. 2003 Aug; 80(3):303-11. 13. Aceto G, Penza R, Coccioli MS, Palumbo F, Cresta L, Cimador M, Chiozza ML, Caione P. Enuresis subtypes based on nocturnal hypercalciuria: a multicenter study. J Urol. 2003 Oct; 170(4 Pt 2):1670-3. 14. Negri AL, Spivacow R, Del Valle E, Fradinger E, Marino A, Zanchetta JR. Renal phosphate leak in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urol Res. 2003 Sep 13. 15. Garcia-Nieto V, Navarro JF, Monge M, Garcia-Rodriguez VE. Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephron Clin Pract. 2003; 94(4):c89-93. 16. Weisinger JR. Bone mineral density in idiopathic hypercalciuria:the chicken or the egg? Nephron Clin Pract. 2003; 94(4):c81-2. 17. Rake JP, Visser G, Huismans D, Huitema S, van der Veer E, Piers DA, Smit GP. Bone mineral density in children adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study. J Inherit Metab Dis. 2003; 26(4):371-84. 18. Winer KK, Ko CW, Reynolds JC, Doedy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003 Sep; 88(9):4214-20. PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com
  • 6. 6 19. Mittal RD, Kumar R, Mittl B, Prasad R, Bhandari M. Stone composition, Metabolic Profile and the Presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract. 2003 Oct-Dec; 12(4):208-13. 20. Ogawa Y, Yonou H, Hokama S, Oda M, Morozumi M, Sugaya K. Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24-hour urine specimens. Front Biosci. 2003 Sep 1; 8:a167-76. PDF Created with deskPDF PDF Creator X - Trial :: http://www.docudesk.com